Moderna (MRNA) Tops Q2 EPS by 32c
Moderna (NASDAQ: MRNA) reported Q2 EPS of ($3.62), $0.32 better than the analyst estimate of ($3.94). Revenue for the quarter came in at $344 million versus the consensus estimate of $307.65 million.
Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination rates.
For earnings history and earnings-related data on Moderna (MRNA) click here.